Efficasy, safety, and pharmacokinetics results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Wilebrand Factor (WVF)/factor VIII (FVIII) concentrate (Voncento) in subjects with hemophilia A (the SWIFT-HA Study)

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/10727

Title:	Efficasy, safety, and pharmacokinetics results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Wilebrand Factor (WVF)/factor VIII (FVIII) concentrate (Voncento) in subjects with hemophilia A (the SWIFT-HA Study)
Authors:	A. Klukowska A. Skotnicki T. Lissitchkov V. Mamonov E. Buevich K. Kuliczkowski S. Goranov J. Kolczko S. Stankovic W. Seifert
Keywords:	hemophilia A plasma-derived concentrate SWIFT-HA study
Issue Date:	2014
Journal:	Haemophilia
Conference:	World Federation of Hemophilia (WFH) World Congress 2014, Melbourne, Australia
URI:	http://hdl.handle.net/20.500.12188/10727
Appears in Collections:	Faculty of Medicine: Conference papers

File	Size	Format
WFH 2014 World Congress Abstract book.jpg	168.66 kB	JPEG	View/Open
poster Hemophilia 2014.jpg	216.49 kB	JPEG	View/Open
abstract (Hemophilia 2014).jpg	233.12 kB	JPEG	View/Open